Evofem Biosciences, Inc.
EVFM
$0.01
$0.002.67%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -45.43% | 6.39% | 34.59% | 10.14% | 15.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -45.43% | 6.39% | 34.59% | 10.14% | 15.99% |
| Cost of Revenue | -32.32% | 12.33% | 71.43% | 4.14% | -1.82% |
| Gross Profit | -47.86% | 1.88% | 24.62% | 11.58% | 20.02% |
| SG&A Expenses | -12.64% | -10.07% | -43.81% | -17.56% | -0.93% |
| Depreciation & Amortization | -86.92% | -66.37% | -72.01% | -73.42% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.70% | 955.60% | -23.33% | -14.45% | 9.50% |
| Operating Income | -98.96% | -1,497.25% | 433.50% | 59.75% | 9.94% |
| Income Before Tax | -521.05% | -671.76% | 191.77% | 33.71% | -230.76% |
| Income Tax Expenses | -- | -- | -- | 50.00% | -12.50% |
| Earnings from Continuing Operations | -518.61% | -671.65% | 191.80% | 33.66% | -232.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -518.61% | -671.65% | 191.80% | 33.66% | -232.05% |
| EBIT | -98.96% | -1,497.25% | 433.50% | 59.75% | 9.94% |
| EBITDA | -116.75% | -907.55% | 605.74% | 57.90% | 17.51% |
| EPS Basic | -447.97% | -608.64% | 166.32% | 43.09% | -175.90% |
| Normalized Basic EPS | -336.96% | -601.96% | 166.48% | -27.08% | -172.44% |
| EPS Diluted | -447.97% | -20,700.00% | 100.69% | 43.09% | -1,950.00% |
| Normalized Diluted EPS | -336.96% | -25,700.00% | 100.56% | -27.08% | -1,940.00% |
| Average Basic Shares Outstanding | 13.98% | 12.76% | 37.96% | 23.97% | 80.45% |
| Average Diluted Shares Outstanding | 13.98% | -97.84% | 23,852.46% | 23.97% | -92.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |